<div id="readability-page-1"><div><p>Fate Therapeutics (FATE) opened 2026 with Q1 results showing revenue of about US$1.3 million and a basic EPS loss of US$0.26, alongside a net loss of US$31.2 million. Over recent quarters the company has seen quarterly revenue sit in a tight band around US$1.3 million to US$1.9 million, while basic EPS losses have moved between roughly US$0.26 and US$0.44 and trailing twelve month EPS has been around a US$1.09 loss. With the stock trading near US$1.90, the key question for investors is whether the current loss profile and negative margins are a reasonable trade off for the growth potential implied by Fate Therapeutics' pipeline and projected top line expansion.</p> <p>See our full analysis for Fate Therapeutics.</p><p>With the headline numbers on the table, the next step is to see how this latest quarter lines up against the widely held narratives around Fate Therapeutics' growth potential, risk profile, and path toward improving margins.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d4ec38e-4ee8-445a-a986-7954fb99fef1/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTE1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d4ec38e-4ee8-445a-a986-7954fb99fef1/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTE1"/><figcaption>NasdaqGM:FATE Earnings &amp; Revenue History as at May 2026</figcaption></figure> <h2>TTM losses at US$129.9 million keep margins deep in the red</h2> <ul> <li>On a trailing twelve month basis, Fate reported total revenue of US$6.3 million against a net loss of US$129.9 million and an EPS loss of US$1.09, which shows the current business is still heavily loss making relative to its size.</li> <li>Critics highlight that the company is forecast to remain unprofitable with earnings expected to decline about 0.8% per year for the next three years, and the recent quarterly net losses between about US$31 million and US$38 million since early 2025 keep that bearish concern front and center.     <ul> <li>The pattern of quarterly EPS losses between roughly US$0.26 and US$0.44 and trailing twelve month losses above US$120 million aligns with the view that profitability is not close based on current trends.</li> <li>The major risk flagged is that, even as revenue forecasts look strong, reported earnings are expected to weaken slightly, so bears see limited evidence in these figures of a near term path to break even.</li> </ul> </li> </ul><p> Stay grounded in the full bear case before making any big decisions on a stock that is still heavily loss making.<strong>🐻 Fate Therapeutics Bear Case</strong></p><h2>High 35.1x P/S multiple leans on strong revenue forecasts</h2> <ul> <li>With a P/S ratio of 35.1x compared with the US Biotech industry at 10.6x and peers at 18.1x, the stock trades at a rich premium that depends heavily on the forecast 64.4% yearly revenue growth.</li> <li>Supporters argue that the forecast revenue growth rate of about 64.4% per year and the five year trend of shrinking losses at roughly 9% per year together help justify a higher multiple, yet the current US$6.3 million trailing revenue and US$129.9 million trailing loss numbers make it important to question how much optimism is already in the price.     <ul> <li>The rewards summary points to revenue growth expected to outpace the broader US market at 11.6% per year, which backs the bullish focus on the top line even though profitability remains distant.</li> <li>At the same time, the combination of a 35.1x P/S and continuing losses may limit the room for error if the revenue ramp does not materialize at the speed implied by those forecasts.</li> </ul> </li> </ul> <h2>Sequential losses narrow from US$52.2 million to about US$31.2 million</h2> <ul> <li>Comparing recent quarters, net loss moved from US$52.2 million in Q4 2024 to a range of about US$37.6 million to US$31.2 million over the four quarters since, while quarterly revenue has stayed in a tight band between about US$1.3 million and US$1.9 million.</li> <li>What stands out against the more cautious narrative is that over the past five years reported losses have been reduced at an average rate of about 9% per year, and the trailing twelve month loss has declined from US$186.3 million in Q4 2024 to US$129.9 million in Q1 2026, which partly offsets the bearish focus on continued unprofitability.     <ul> <li>The EPS trend shows trailing twelve month loss per share easing from US$1.64 in Q4 2024 to US$1.09 by Q1 2026, giving some numeric backing to the reward statement about multi year improvement in earnings even though the company stays in the red.</li> <li>Investors weighing these figures against the warnings about an expected 0.8% yearly decline in earnings may see a tension between backward looking improvement in losses and the more cautious forward looking forecasts.</li> </ul> </li> </ul><p> If you want to see how other investors connect these loss trends, revenue forecasts, and valuation, check out the wider community view on the stock.<strong>📊 Read the what the Community is saying about Fate Therapeutics.</strong></p><h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Fate Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>Balancing these mixed signals on losses, revenue forecasts, and valuation can feel challenging, so act quickly, review the data yourself, and weigh both the 2 key rewards and 3 important warning signs</p> <h2>Explore Alternatives</h2> <p>Fate Therapeutics is still heavily loss making with trailing twelve month losses of US$129.9 million, a 35.1x P/S multiple, and no clear path to profitability.</p> <p>If you want ideas where pricing is less demanding and current financials look more resilient, compare this stock with companies in the 67 resilient stocks with low risk scores.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

FATE

SBIO

LABU

IBBQ

<p>Fate Therapeutics (FATE) reported Q1 losses of $31.2 million and a basic EPS loss of $0.26, raising concerns over its high 35.1x P/S valuation. Despite a forecasted 64.4% annual revenue growth, the company remains heavily unprofitable with trailing losses of $129.9 million. Investors are cautious as earnings are expected to decline by 0.8% annually over the next three years, questioning the sustainability of the stock's premium valuation amidst ongoing losses.</p>

Simplywall

Fate Therap

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation